Eli Lilly: Weekly Insulin Dose On Par With Common Daily Doses - Eli Lilly and Co (NYSE:LLY)
Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes.
Related Keywords
Eli Lilly , Price Action , Pfizer Follows Eli Lilly ,
comparemela.com © 2020. All Rights Reserved.